Viatris Agrees to Acquire Pacira BioSciences for $1.65 Billion in Non-Opioid Pain Therapy Expansion
Viatris (VTRS) will acquire Pacira BioSciences (PCRX) for $1.65B ($36.50 per share), adding two pain therapies to its portfolio. Pacira generated $746M revenue and $177M EBITDA in the last 12 months. The deal is expected to close by the end of 2026 and be immediately accretive to Viatris' financials.
How this was made
The 30-second read
Why it matters
The deal is positioned as immediately accretive, adding $746 M revenue and $177 M EBITDA, funded largely by cash, with minimal leverage impact.
Market read
The acquisition creates a larger non‑opioid portfolio for Viatris, likely moving both stocks on the announcement.
What to watch
Potential regulatory scrutiny of the tender offer and the need for Pacira shareholders to tender enough shares for deal closure.
Background
Viatris seeks to expand its specialty medicines business through the acquisition of Pacira's established non‑opioid pain therapies.
Ticker impact
Viatris announced a $1.65 B cash acquisition of Pacira, offering $36.50 per share, which is expected to be immediately accretive to its guidance.
upward pressure as the market prices in the immediate earnings accretion and expanded product portfolio
The deal adds $746 M of revenue and $177 M of adjusted EBITDA, funded mostly with excess cash, and is expected to close by year‑end.
Pacira BioSciences agreed to be acquired for $36.50 per share in cash, ending its independent trading on Nasdaq.
downward pressure as the market aligns the stock with the $36.50 cash offer
The transaction will delist Pacira; cash consideration sets a clear floor, prompting a sell‑off to the offer price.
Market effects
Strengthens the specialty pharma and non‑opioid pain‑management segment, potentially prompting peers to reassess pipelines.
U.S. market focus; limited immediate effect on international markets beyond Viatris' global footprint.
Adds a sizable non‑opioid portfolio to a global generic leader, modestly influencing worldwide pharma M&A sentiment.
Counterpoint
If integration costs exceed expectations, the accretion could be overstated, weighing on Viatris.
Key entities
- CompanyViatris
NASDAQ‑listed generic and specialty pharma company acquiring Pacira.
- CompanyPacira BioSciences
NASDAQ‑listed developer of non‑opioid pain treatments being acquired.
